Helus Pharma Inc. Common Stock
HELP
61 hedge funds and large institutions have $1.56M invested in Helus Pharma Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.73% less ownership
Funds ownership: 3.89% → 2.16% (-1.7%)
8% less funds holding
Funds holding: 66 → 61 (-5)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
45% less capital invested
Capital invested by funds: $2.84M → $1.56M (-$1.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$44.3K |
| 2 |
ICG
InterOcean Capital Group
Nashville,
Tennessee
|
+$31.7K |
| 3 |
LPL Financial
San Diego,
California
|
+$8.84K |
| 4 |
Cerity Partners
New York
|
+$6.65K |
| 5 |
MWM
Marietta Wealth Management
Marietta,
Georgia
|
+$6.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$823K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$144K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$121K |
| 4 |
VF
Virtu Financial
New York
|
-$55K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$37.5K |
HELP Hedge Fund Activity: Q2 2023 in Review
61 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Helus Pharma Inc. Common Stock (HELP) for Q2 2023, worth a combined $1.56M — down 45% from $2.84M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HELP and 7 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $44.3K. The largest seller was Morgan Stanley, cutting an estimated $823K.
- 61 institutional investors held Helus Pharma Inc. Common Stock (HELP) as of Q2 2023, down from 66 in Q1 2023.
- Funds reported $1.56M of Helus Pharma Inc. Common Stock stock for Q2 2023, down 45% quarter-over-quarter.
- 7 funds opened new Helus Pharma Inc. Common Stock positions in Q2 2023 and 12 closed out, a net change of -5 holders.
- The largest Helus Pharma Inc. Common Stock buyer in Q2 2023 was FNY Investment Advisers, an estimated $44.3K added.
- The largest Helus Pharma Inc. Common Stock seller in Q2 2023 was Morgan Stanley, an estimated $823K sold.
Based on aggregated 13F filings for Q2 2023.